Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-24-050111
Filing Date
2024-12-05
Accepted
2024-12-05 17:04:21
Documents
1
Period of Report
2024-11-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1733436254.html 4  
1 FORM 4 wk-form4_1733436254.xml 4 32059
  Complete submission text file 0001628280-24-050111.txt   33480
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2525 WEST END AVE., SUITE 950 NASHVILLE TN 37203
Business Address
Jones James (Reporting) CIK: 0001490829 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 241529823